Form 4: Catalyst Pharmaceuticals Director Molly Harper Acquires Shares and Options

Director Molly Harper of Catalyst Pharmaceuticals acquired stock options and restricted stock units, increasing her beneficial ownership in the company.

Summary

• Molly Harper, a director at Catalyst Pharmaceuticals, acquired 23,248 options to purchase common stock at an exercise price of $21.12 on November 21, 2024.
• These options vest in three equal tranches on November 21, 2025, 2026, and 2027.
• Harper also acquired 2,841 restricted stock units (RSUs) on the same date, each representing a contingent right to receive one share of common stock upon vesting.
• Following these transactions, Harper's direct holdings increased to 148,679 shares of common stock and 151,520 RSUs.
• The transactions were reported on November 25, 2024.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedule of the options and RSUs encourages long-term alignment with shareholder interests.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• The vesting schedule of the options and RSUs is typical for executive compensation packages in the pharmaceutical industry.
• The acquisition of shares and options by a director is a common practice to align their interests with those of the shareholders.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement for publicly traded companies.

Stakeholder Impact

• The acquisition of shares and options by a director can be viewed positively by shareholders as it indicates confidence in the company's future.

Key Dates

Keywords

Catalyst Pharmaceuticals, Molly Harper, stock options, restricted stock units, insider trading, beneficial ownership, director